Role of ethnicity in predicting antipsychotic medication adherence

Annals of Pharmacotherapy

Volumn 37, Issue 5, 2003, Pages 625-630

  Opolka, Jayme L ^a   Rascati, Karen L ^b   Brown, Carolyn M ^b   Gibson, P Joseph ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adherence; Antipsychotics; Ethnicity; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BODY WEIGHT DISORDER; CAUCASIAN; COMORBIDITY; DRUG USE; DYSKINESIA; ETHNIC GROUP; ETHNOLOGY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; ETHNIC GROUPS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0242668298     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C321     Document Type: Article

References (25)

1. The Schizophrenia homepage. www.schizophrenia.com (accessed 2001 Jan 31).
2. Schizophrenia. National Institute of Mental Health.www.nimh.nih.gov (accessed 2001 Mar 16).
3. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Rev 2000;31:106-12.
4. Fabrega H, Mezzich J, Ulrich RF. African American-white differences in psychopathology in an urban psychiatric population. Compr Psychiatry 1988;29:285-97.
5. Lawson WB. Racial and ethnic factors in psychiatric research. Hosp Commun Psychiatry 1986;37:50-4.
6. Jeste DV, Lindamer LA, Evans J, Lacro JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996;32:243-51.
7. Henderson DC. Treatment-resistant schizophrenia in African Americans. In: Herrera JM, Lawson WB, Sramek JJ, eds. Cross cultural psychiatry. Chickester, England: John Wiley & Sons. 1999:166-8.
8. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics, Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85.
9. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
10. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
11. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
12. Frankenburg FR. Choices in antipsychotic therapy in schizophrenia. Harv Rev Psychiatry 1999;6:241-9.
13. International classification of diseases. 9th rev. Clinical modification. Washington, DC: Department of Health and Human Services, 2001.
14. Choo PW, Rand CS, Inui TS, Lee MT, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57.
15. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9.
16. Lawson WB. Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol Bull 1996;32:275-81.
17. Frackiewicz EJ, Sramek JJ, Collazo Y, Rotaru E, Herrera JM. Risperidone in the treatment of Hispanic schizophrenic patients. In: Herrera JM, Lawson WB, Sramek JJ, eds. Cross cultural psychiatry. Chickester, England: John Wiley & Sons, 1999:184.
18. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002;94:1-26.
19. The Texas State Board of Medical Examiners homepage. www.tsbme.state.tx.us/demo/docs/d2002/0902/ethnic.htm (accessed 2002 Oct 13).
20. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569-75.
21. Ruiz P. Access to health care for uninsured Hispanics: policy recommendations. Hosp Commun Psychiatry 1993;44:958-62.
22. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Commun Psychiatry 1994;45:38-42.
23. Ruiz S, Chu P, Collazo Y, Tam R, Sramek JJ, Herrera JM. Neuroleptic dosing in Hispanics and Asian patients with schizophrenia. In: Herrera JM, Lawson WB, Sramek JJ, eds. Cross cultural psychiatry. Chickester, England: John Wiley & Sons, 1999:163.
24. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
25. Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. Psychopharmacology 2001;156:53-7.